VJHemOnc is committed to improving our service to you

ICML 2019 | Acalabrutinib-obinutuzumab in CLL: 3-year follow-up

VJHemOnc is committed to improving our service to you

Kerry Rogers

The combination of acalabrutinib with obinutuzumab was investigated for the treatment of chronic lymphocytic leukemia (CLL) in the Phase 1b/2 ACE-CL-003 study (NCT02296918). Here, Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the 3-year follow-up. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter